These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 31383341)

  • 21. Efficacy and safety of anti-interleukin-1 in children with colchicine-resistant familial Mediterranean fever.
    Erkilet HK; Gezgin Yildirim D; Esmeray P; Söylemezoğlu O
    Pediatr Int; 2023; 65(1):e15588. PubMed ID: 37658625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [INTERLEUKIN 1 INHIBITORS--A NEW HORIZON IN THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER].
    Shouval R; Livneh A; Ben-Zvi I
    Harefuah; 2015 Nov; 154(11):716-9, 741. PubMed ID: 26821505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of interleukin-1 blockers in kidney transplant recipients with familial Mediterranean fever: a propensity score-matched cohort study.
    Mirioglu S; Dirim AB; Bektas M; Demir E; Tor YB; Ozluk Y; Kilicaslan I; Oto OA; Yalcinkaya Y; Caliskan Y; Artim-Esen B; Yazici H; Inanc M; Turkmen A; Gul A; Sever MS
    Nephrol Dial Transplant; 2023 May; 38(5):1327-1336. PubMed ID: 36542475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Familial mediterranean fever: a fascinating model of inherited autoinflammatory disorder.
    Portincasa P; Scaccianoce G; Palasciano G
    Eur J Clin Invest; 2013 Dec; 43(12):1314-27. PubMed ID: 24117178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Colchicine treatment of AA amyloidosis of familial Mediterranean fever. An analysis of factors affecting outcome.
    Livneh A; Zemer D; Langevitz P; Laor A; Sohar E; Pras M
    Arthritis Rheum; 1994 Dec; 37(12):1804-11. PubMed ID: 7986228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Approach to the patients with inadequate response to colchicine in familial Mediterranean fever.
    Gül A
    Best Pract Res Clin Rheumatol; 2016 Apr; 30(2):296-303. PubMed ID: 27886801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever.
    Alpay N; Sumnu A; Calışkan Y; Yazıcı H; Türkmen A; Gül A
    Rheumatol Int; 2012 Oct; 32(10):3277-9. PubMed ID: 20386914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complete remission of nephrotic syndrome in a woman with renal amyloidosis due to familial mediterranean fever.
    Heras M; Saiz A; Fernández-Reyes MJ; Molina Á; Astrid Rodríguez M; Callejas R
    Nefrologia; 2016; 36(3):331-2. PubMed ID: 26560399
    [No Abstract]   [Full Text] [Related]  

  • 29. Effect of anti-interleukin-1 treatment on quality of life in children with colchicine-resistant familial Mediterranean fever: A single-center experience.
    Kurt T; Aydın F; Nilüfer Tekgöz P; Sezer M; Uncu N; Çelikel Acar B
    Int J Rheum Dis; 2020 Jul; 23(7):977-981. PubMed ID: 32558310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Familial Mediterranean fever: not to be missed].
    Frenkel J; Bemelman FJ; Potter van Loon BJ; Simon A
    Ned Tijdschr Geneeskd; 2013; 157(18):A5784. PubMed ID: 23635502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is colchicine therapy effective in all patients with secondary amyloidosis?
    Unverdi S; Inal S; Ceri M; Unverdi H; Batgi H; Tuna R; Ozturk MA; Guz G; Duranay M
    Ren Fail; 2013 Sep; 35(8):1071-4. PubMed ID: 23841746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever.
    Calligaris L; Marchetti F; Tommasini A; Ventura A
    Eur J Pediatr; 2008 Jun; 167(6):695-6. PubMed ID: 17588171
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever.
    Ugurlu S; Hacioglu A; Adibnia Y; Hamuryudan V; Ozdogan H
    Orphanet J Rare Dis; 2017 May; 12(1):105. PubMed ID: 28558744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel therapeutics for the treatment of familial Mediterranean fever: from colchicine to biologics.
    Grattagliano I; Bonfrate L; Ruggiero V; Scaccianoce G; Palasciano G; Portincasa P
    Clin Pharmacol Ther; 2014 Jan; 95(1):89-97. PubMed ID: 23867542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Familial mediterranean fever-related nephrotic syndrome and successful full-term pregnancy.
    Tutuncu L; Atasoyu EM; Evrenkaya R; Mungen E
    Arch Med Res; 2006 Jan; 37(1):178-80. PubMed ID: 16314207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative Review.
    Hentgen V; Vinit C; Fayand A; Georgin-Lavialle S
    Front Immunol; 2020; 11():971. PubMed ID: 32670263
    [No Abstract]   [Full Text] [Related]  

  • 37. Efficacy of anakinra in a patient with systemic amyloidosis presenting as amyloidoma.
    Nalcacioglu H; Ozkaya O; Genc G; Ayyildiz S; Kefeli M; Elli M; Aydin O; Ceyhan Bilgici M
    Int J Rheum Dis; 2018 Feb; 21(2):552-559. PubMed ID: 29239128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Toxic myopathy with kidney failure as a colchicine side effect ifn familial Mediterranean fever].
    Stefanidis I; Böhm R; Hägel J; Maurin N
    Dtsch Med Wochenschr; 1992 Aug; 117(33):1237-40. PubMed ID: 1499522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Preferential Use of Anakinra in Various Settings of FMF: A Review Applied to an Updated Treatment-Related Perspective of the Disease.
    Giat E; Ben-Zvi I; Lidar M; Livneh A
    Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AA type renal amyloidosis secondary to FMF: a long-term follow-up in two patients.
    Aybal Kutlugün A; Yildirim T; Altindal M; Arici M; Yasavul U; Turgan C
    Ren Fail; 2010; 32(10):1230-2. PubMed ID: 20954987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.